As in studies that were previously performed in IDH-mutant leukemias [10,41], future studies should investigate whether the highly sensitive BEAMing methodology may be able to detect co-occurring clonal or sub-clonal IDH mutations in tumor tissue, as well as co-ocurring mutations in other genes that elude detection by NGS but may aid in the more accurate mutational profiling of these tumors [5,40,41]. The gene discussed is IDH2; the disease is neoplasm.